Korro Bio (KRRO) Operating Leases (2020 - 2026)

Korro Bio (KRRO) has reported Operating Leases for 7 consecutive years, with $42.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 5.42% year-over-year to $42.2 million; the trailing twelve-month figure through Jun 2026 stood at $42.2 million (down 5.42% YoY), and the FY2025 full-year result was $40.8 million, down 6.13% from the prior year.
• Operating Leases eased to $42.2 million in Q2 2026 per KRRO's latest filing, from $42.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $45.2 million in Q1 2025 and bottomed at $209000.0 in Q4 2022.
• Historically, Operating Leases has averaged $34.4 million across 5 years, with a median of $38.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Leases slumped 99.28% in 2022, then jumped 14835.89% in 2023.
• Over 5 years, Operating Leases stood at $209000.0 in 2022, then surged by 14835.89% to $31.2 million in 2023, then jumped by 39.29% to $43.5 million in 2024, then fell by 6.13% to $40.8 million in 2025, then rose by 3.43% to $42.2 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $42.2 million, $42.9 million, and $40.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.